

Learning Objectives
2019 OPA Compound Conference

ACPE #0129-0000-19-071-L07-P/T

National Compounding Scene...What's Important Right Now

Scott Brunner, CAE; Executive Vice President, International Academy of Compounding Pharmacists

At the completion of this activity, the pharmacist/technician participant will be able to:

1. describe provisions of the current proposed FDA memorandum of understanding with states and how those provisions will affect dispensing and distribution of – and patient access to – compounded medications;
2. explain effect of the new USP <797> on BUD extensions, as well as the implications for patient access to compounded medications;
3. explain likely enforcement mechanisms for USP <800>;
4. recognize the value of representation on FDA's Pharmacy Compounding Advisory Committee (PCAC) of compounding pharmacists with patient-facing experience; and
5. describe the effects of FDA's actions on bulk substance lists on FDA's plans for 503B outsourcing facilities to provide compounded substances for office use.

ACPE #0129-0000-19-072-L07-P/T

Compounded Veterinary Medications from a "Pharmacist-Turned Veterinarian" Point of View

Alice Jeromin, R.Ph., DVM, DACVD; Veterinary Allergy and Dermatology, Inc.

At the completion of this activity, the pharmacist/technician participant will be able to:

(Pharmacists)

1. describe the more commonly compounded veterinary medications and recognize their key characteristics including how safe, how stable, and for how long?
2. explain the main species differences between human and veterinary medications
3. discuss the clinical applications of commonly used human medications in veterinary medicine
4. identify important considerations when recommending OTC medications for dogs and cats

(Technicians)

1. describe the more commonly compounded veterinary medications and recognize their key characteristics including how safe, how stable, and for how long?
2. explain the main species differences between human and veterinary medications
3. discuss the clinical applications of commonly used human medications in veterinary medicine

ACPE #0129-0000-19-073-L07-P/T

Changing Compounding Regulations... Here's the Latest

Ross Caputo, PhD; President, Eagle, a PCCA company

At the completion of this activity, the pharmacist/technician participant will be able to:

1. discuss changes to USP <795> chapter on non-sterile compounding;
2. describe changes to USP <797> chapter on sterile compounding; and
3. explain how to implement procedural changes in pharmacy operations to comply with new chapters and mitigate regulatory risk.

ACPE #0129-0000-19-074-L07-P/T

Why Topical Formulations Fail

Ken Alexander, R.Ph., PhD; Consultant, Pharm Serv & Tech

At the completion of this activity, the pharmacist/technician participant will be able to:

1. explain why his/her perfectly compounded topical formulation is ineffective;
2. translate the pharmaceutical alphabet soup in order to understand the theoretical jargon; and
3. discuss how to rationally consider all factors required for effective therapeutic topical drug delivery.